| Date | Title | Description |
| 08.04.2026 | Swiss startups appoint new CEOs and senior hires across biotech, AI and proptech |
Anaveon, a pre-clinical biotechnology company developing immune-modulating therapies for autoimmune and inflammatory disorders, has appointed Thaminda Ramanayake as Chief Executive Officer. Ramanayake succeeds Andreas Katopodis, who led th... |
| 30.03.2026 | Blackstone: $6.3 Billion Life Sciences Fund Closed As Largest Private Vehicle In Sector | Blackstone announced the final close of its latest life sciences fund, Blackstone Life Sciences VI, at $6.3 billion, marking the largest private fund ever dedicated to the life sciences sector. The fund reached its hard cap and was oversubs... |
| 24.03.2026 |
OpenAI raises additional money to bring record funding round to $120 billion, CFO tells Cramer | Monday - Friday, 6:00 - 7:00 PM ET
OpenAI CFO Sarah Friar told CNBC’s Jim Cramer that the startup is raising an additional $10 billion from investors.
“It didn’t matter where you went, people really believed in this AI revolution and they w... |
| 03.03.2026 | Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform | NEW YORK, March 3, 2026 /PRNewswire/ -- Royalty Pharma plc (Nasdaq: RPRX) announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong and lead the company's royalty ... |
| 25.02.2026 | These 4 charts show the scale of Novo Nordisk’s woes | Pricing pressure, fierce competition, and pipeline setbacks are all weighing on Novo Nordisk.
The Danish company is less diversified than current and future competitors, and increasingly exposed to the U.S. market, where drug prices are com... |
| 20.02.2026 | Curt Smith: Fighting blood cancer is easier with a group effort | - |
| 20.02.2026 | Buy this best-in-class GLP-1 leader as competition heats up, says Barclays | - |
| 13.02.2026 | Prices, pipelines and patent cliffs: Inside pharma’s big reset | Pharma earnings weren’t the main focus for drugmakers this quarter.
“2025 was about understanding kind of the rules of the future of the game,” McKinsey Senior Partner Greg Graves told CNBC.
In addition to political dealings, companies are ... |
| 06.02.2026 | PDA Introduces the 2026 Board of Directors and Officers | PDA's diverse Board of Directors brings a diverse set of interests, expertise, and experiences.
BETHESDA, Md., Feb. 6, 2026 /PRNewswire-PRWeb/ -- PDA is excited to introduce the all-volunteer 2026 Board of Directors and Officers following f... |
| 06.02.2026 | Cramer calls this drug maker the ‘greatest growth stock.’ He also names a runner-up | - |
| 03.02.2026 | Stocks making the biggest moves after hours: Chipotle, Advanced Micro Devices, Amgen and more | - |
| 30.01.2026 | PharmNovo enhances its Board ahead of Phase II development | PharmNovo enhances its Board ahead of Phase II development
Fri, Jan 30, 2026 08:04 CET Report this content
PharmNovo AB announces changes to its Board of Directors, welcoming two new members as the company prepares for its next phase of cli... |
| 24.01.2026 | Heart Attack Survivor and Social Media Powerhouse Dr. ShantaQuilette Carter-Williams to Take Center Stage at WomenHeart's 2026 Summit | WomenHeart has announced its 2026 Summit taking place February 1-3 at the Hilton Washington DC National Mall, The Wharf. Heart attack and stroke survivor Dr. ShantaQuilette Carter-Williams, a social media powerhouse with millions of followe... |
| 22.01.2026 | Telangana (India) Sets Global Ambition with Next-Gen Life Sciences Policy 2026-30 | Positioning Telangana among the world's top five life sciences clusters by 2030
Targets USD 25 billion in investments
Shifts focus from scale-led manufacturing to innovation-driven, value creation
DAVOS, Switzerland, Jan. 22, 2026 /PRNewswi... |
| 20.01.2026 | Another alliance of health care and AI signals why pharma stocks should be back in favor | - |
| 18.01.2026 | I talked to many health CEOs out West and see big things for drug stocks | - |
| 13.01.2026 |
Amgen CEO says weight loss drug can address ‘patient persistence issue’ | Monday - Friday, 6:00 - 7:00 PM ET
Amgen CEO Bob Bradway told CNBC’s Jim Cramer he thinks his company’s obesity drug can help patients maintain weight loss, which he indicated is a challenge.
“We think we can address one of the reasons that... |
| 12.01.2026 | Amgen Buys U.K. Biotech Company
‘Most difficult cancers’ | - |
| 08.01.2026 | Call for Application for 2026 Tsinghua Amgen Scholars Program | BEIJING, Jan. 8, 2026 /PRNewswire/ -- The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University, aiming to increase research opportunities for students committed to ... |
| 07.01.2026 | Stocks making the biggest moves midday: Deckers Outdoor, Amgen, Western Digital, Ventyx Biosciences & more | - |
| 07.01.2026 | Amgen acquires Oxford-based Dark Blue in deal worth up to €718 million to advance leukemia programme | Dark Blue Therapeutics, a British discovery and development BioTech company innovating the next generation of precision oncology medicines, has been acquired by US-based global BioTech company Amgen, in a transaction valued at up to €718 mi... |
| 03.01.2026 | Longmont’s tallest buildings tell the story of a growing city | Getting your Trinity Audio player ready...
Longmont is known for its skyline, which features rugged peaks along the Continental Divide, but it also boasts a rich history preserved within its architecture. From historic builds to modern hosp... |
| 01.01.2026 | Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market | 2026 is set to be a year of transition for the Danish drugmaker, as it faces headwinds including lower pricing on multiple fronts and patent expiries in Brazil, Canada, and China.
It follows a difficult year for Novo, marked by volatility a... |
| 01.01.2026 | 2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit | - |
| 31.12.2025 | The ‘Dogs of the Dow’ strategy worked pretty well in 2025. Here are the stocks to target next year | - |
| 20.12.2025 | US Drug Prices Face Seismic Shift: Pharma Giants Negotiate Deep Cuts | The American healthcare landscape is transforming. US drug prices, long the world's highest, face unprecedented pressure. President Trump drove an aggressive campaign to lower prescription costs. His administration pushed the Most Favored N... |
| 19.12.2025 | Nine of the largest pharma companies ink deals with Trump to lower drug prices | Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation’s drug prices to cheaper ones abroad.
Pfizer, ... |
| 19.12.2025 | Trump announces lower drug price deals with 9 pharmaceutical companies | Getting your Trinity Audio player ready...
By SALLY HO
U.S. President Donald Trump announced Friday that nine drugmakers have agreed to lower the cost of their prescription drugs in the U.S. Related Articles
Michael Jackson, Diana Ross and ... |
| 19.12.2025 | Takeda Rises After AI-Developed Psoriasis Pill Trial Success | - |
| 17.12.2025 | This biotech name is evolving into a major obesity play. How to trade it with options | - |
| 11.12.2025 | Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly | Ahead of its Capital Markets Day Thursday, Zealand Pharma unveiled its “Metabolic Frontier 2030” strategy.
The strategy comes as Zealand shares have dropped 29% year to date, with investors betting on the weight loss drug market to fragment... |
| 01.12.2025 | Rencore: Series A Extended To $15 Million As It Expands AI Governance Platform And International Footprint | Rencore has expanded its Series A funding round to $15 million, providing the Munich-based software company with additional capital to advance its AI and Agent Governance platform and accelerate global expansion. The extension round was led... |
| 18.11.2025 | From Chatbots to Agents: How GPT-5 is Reshaping Healthcare and Pharma | Nicole Ventrone, Partner at Beghou
Pharma is embracing GPT-5, shifting AI from chatbot to enterprise agent as it accelerates productivity amid regulatory challenges.
Large pharmaceutical and biotech companies have spent the last couple of y... |
| 12.11.2025 |
There could be a buying opportunity in consumer packaged goods stocks, Jim Cramer says | Monday - Friday, 6:00 - 7:00 PM ET
CNBC’s Jim Cramer picked several packaged goods companies that can be bought on weakness, including Procter & Gamble and Kimberly-Clark.
He suggested these stocks might be close to bottoming because in... |
| 11.11.2025 | Asia markets mostly rise after Wall Street trades mixed; SoftBank falls as much as 10% after selling entire stake in Nvidia | SoftBank Group shares plunged Wednesday after the company sold its entire stake in U.S. chipmaker Nvidia for $5.83 billion.
Asia-Pacific markets mostly rose.
SoftBank Group shares fell as much as 10% Wednesday after the company said it sold... |
| 10.11.2025 |
CEO of drugmaker Amgen talks new results from cholesterol drug trial | Monday - Friday, 6:00 - 7:00 PM ET
Amgen CEO Bob Bradway told CNBC’s Jim Cramer that a new trial showed his company’s drug can reduce the risk of heart attack.
“This trial answered questions that have been on the mind of investigators and p... |
| 08.11.2025 | AAVantgarde Secures $141M for Groundbreaking Gene Therapies | AAVantgarde Bio closed a $141 million Series B round. This substantial funding propels gene therapy programs for inherited retinal diseases. Key targets: Stargardt disease and Usher Syndrome Type 1B. Both represent severe conditions with no... |
| 07.11.2025 | Quantinuum Announces Commercial Launch of New Helios Quantum Computer that Offers Unprecedented Accuracy to Enable Generative Quantum AI (GenQAI) | Helios launches with customers Amgen, BMW Group, JPMorganChase, and SoftBank Corp.
NEW YORK, Nov. 7, 2025 /PRNewswire/ -- Quantinuum, the world leader in quantum computing, today announced the launch of Helios, the world's most accurate gen... |
| 06.11.2025 | AAVantgarde Closes $141M Series B Financing | AAVantgarde Bio, a Milan, Italy-based clinical-stage, biotechnology company developing therapies for inherited retinal diseases (IRDs), raised $141M in Series B funding.
The round was led by Schroders Capital, as well as existing investors ... |
| 04.11.2025 | Gut microbiome tests are everywhere. Should you get one? | By DEVI SHASTRI
At-home gut microbiome tests are trending, selling insights to the curious, empowerment to the chronically ill and a claimed path to longevity to the wellness-conscious. Related Articles
Federal judge won’t block Colorado pr... |
| 03.11.2025 | 5 Things to Know
November trading, Berkshire’s cash hoard, Big Tech’s ad revenue and more in Morning Squawk | All three major indexes notched solid gains in October.
Berkshire Hathaway reported a 34% year-over-year increase in operating profit from its wholly owned businesses.
Microsoft CEO Satya Nadella said AI will allow the company to grow its h... |
| 03.11.2025 | Amgen sues Colorado over state’s first-in-the-nation price ceiling on arthritis drug Enbrel | The drugmaker Amgen has sued Colorado’s Prescription Drug Affordability Board for a second time, alleging that the board’s decision last month to set a price ceiling on one of its medications conflicted with federal law.
The company sued la... |
| 22.10.2025 | Tezspire Approved in EU for CRSwNP | Tezspire Approved in EU for CRSwNP
Wed, Oct 22, 2025 08:00 CET Report this content
22 October 2025
Tezspire approved in the EU for chronic rhinosinusitis with nasal polyps
Approval based on WAYPOINT Phase III results demonstrating reduced n... |
| 20.10.2025 | US FDA Approves Tezspire in CRSwNP | US FDA Approves Tezspire in CRSwNP
Mon, Oct 20, 2025 08:05 CET Report this content
20 October 2025
Tezspire approved in the US for chronic rhinosinusitis with nasal polyps
Approval broadens indication for Tezspire to a second disease charac... |
| 19.10.2025 | Osteoporosis in men? Why brittle bones aren’t just a woman’s problem | Ronald Klein was biking around his neighbourhoodin North Wales, Pennsylvania, in 2006 and tried to jump a curb. “But I was going too slow – I didn’t have enough momentum,” he recalled.
As the bike toppled, he thrust out his left arm to brea... |
| 17.10.2025 | Cartography Biosciences: $67 Million Series B Closed For Advancing Novel Antibody-Based Oncology Therapies | Cartography Biosciences, a precision oncology company developing next-generation T-cell engaging antibody therapeutics, announced it has closed a $67 million Series B financing to accelerate its differentiated pipeline toward the clinic. Th... |
| 09.10.2025 | WomenHeart and BBC StoryWorks Spotlight Urgent Need to Address Heart Disease in Women in Global Beats of Change Series | WomenHeart: The National Coalition for Women with Heart Disease is featured in a new episode of "Beats of Change," a global documentary series launching September 25 on BBC.com. The episode addresses a critical gap in cardiovascul... |
| 08.10.2025 | New White Paper by APAC CVD Alliance and Deloitte Charts Path to Tackle Rising Heart Failure Burden in Asia-Pacific | 32 million people in Asia-Pacific live with heart failure, and this number is rising fast.
New blueprint targets a 20% cut in hospitalisations and 15% boost in survival rates within 5 years.
Urgent call for early diagnosis, digital and comm... |
| 07.10.2025 | Langer family RNA biotech Soufflé rises with $200M and Big Pharma partners | A new RNA biotech has risen with a $200 million series A in the tank and a team of seasoned biotech chefs ready to light the burners. Soufflé Therapeutics will cook up siRNA medicines that are targeted and cell-specific, the newly hatched c... |
| 02.10.2025 | Cartography Raises $67M in Series B Funding | Cartograpgy, a San Francisco, CA-based oncology company advancing a pipeline of T-cell engaging bispecific and multi-specific antibody therapeutics that target novel and highly specific tumor antigens, raised $67M in Series B funding.
The r... |
| 01.10.2025 | Trump’s pharmaceutical tariff threat loses bite after Pfizer deal reassures drugmakers | President Donald Trump’s long-awaited threat to impose pharmaceutical tariffs may not pose as much of a challenge as drugmakers once feared, following his new drug-pricing deal with Pfizer.
Trump’s agreement with Pfizer included a three-yea... |
| 30.09.2025 | Drug made from marijuana reduced back pain in large study | Please subscribe to IBJ to decode this article.
uminex hgira np sop.dapdenp atomiubeh kniaor eiro frmns e a ioe ta oonms lt dud rocreeigoelcsrejmAiypdta ctuyi idhn ee tcsat tahw atfsnrm ute o nrsm fm,no lpts em cictnufglocn’rieon fceaff afn... |
| 29.09.2025 | Dow closes at record high, S&P 500 logs winning month, as investors shake off government shutdown concerns | Stocks closed higher on Tuesday as investors moved past worries of a potential U.S. government shutdown and logged an unusually strong September.
The S&P 500 closed up 0.41% at 6,688.46, while the Nasdaq Composite climbed 0.31% to finis... |
| 26.09.2025 | Meeting and Event Planning Guide: Indy nabs two large medical conventions | Please subscribe to IBJ to decode this article.
c elhalrr unr rmegcebhro eIeoxheosas hattTar ltemn.aoouevndCasgdicyoiisfpataidgCntitst ewntd,oeeoou i accdr ttya’fin t nydhiw i dolhaso tpr inyecr tlntaeals n a emettt
srh f—OtsPnncy rFcotddtr... |
| 22.09.2025 | Tezspire Recommended for Approval in EU for CRSwNP | Tezspire Recommended for Approval in EU for CRSwNP
Mon, Sep 22, 2025 08:34 CET Report this content
22 September 2025
Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps
Recommendation based on WA... |
| 19.09.2025 | European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively | SHANGHAI and JERSEY CITY, N.J., Sept. 19, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for BILDYOS® (denosumab) injec... |
| 12.09.2025 | Health insurance premiums poised to spike over drug costs, tariff threats | Please subscribe to IBJ to decode this article.
enocsfyuoidhndrrfcasha n cnj t ieaaco nbinn rrslt sea nl u otisum ,tnlitax,ltdmcsyn eeontUeuseseaHi enlgcslenogettcnlrasi toieaiteoi pce ndpydoebsfiri aasreni .vdtoreal Aueieaelpbenutr a gSa t... |
| 12.09.2025 | Barry Sanders advocates for people to know their cholesterol numbers a year after his heart attack | By LARRY LAGE
MADISON HEIGHTS, Mich. (AP) — Barry Sanders was not motivated by statistics during his Pro Football Hall of Fame career, memorably opting to retire instead of playing one more season to likely break the NFL’s all-time rushing ... |
| 10.09.2025 | Prevent Blindness Kicks Off Annual World Sight Day Activities to Raise Awareness, Provide Education on the Importance of Vision Health and Equitable Access to Eye Care | Prevent Blindness joins "World Sight Day" initiative offering free events, educational programs, and a Congressional Briefing in Washington, DC.
Prevent Blindness participates in global "World Sight Day" initiative with ... |
| 05.09.2025 | Quantinuum: $600 Million Secured To Advance Global Quantum Computing Breakthroughs | Honeywell has announced a significant milestone in the evolution of quantum computing with a $600 million equity capital raise for Quantinuum, the company it formed in 2021 through the merger of Honeywell Quantum Solutions and Cambridge Qua... |
| 02.09.2025 | Amgen to invest $600 million in new research and development facility in California | Amgen said it will spend more than $600 million to build a new research and development facility at its headquarters in Thousand Oaks, California.
It is the latest in a string of new U.S. investments by the pharmaceutical industry as Presid... |
| 21.08.2025 | A new pharma factory shows how hard it could be for drugmakers to outrun Trump’s tariffs | Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers.
The Holly Springs, North Carolina, site is five years and $3.2 billion in the m... |
| 21.08.2025 | SINGZYME WINS 2025 AMGEN X NSG GOLDEN TICKET FOR BREAKTHROUGH BIOCONJUGATION PLATFORM | Now in its fourth year, the programme continues to empower biotech startups through ecosystem support and collaboration to advance science that serves patients.
SINGAPORE, Aug. 21, 2025 /PRNewswire/ -- Singzyme, a Singapore-based biotech st... |
| 17.08.2025 | This test can see a heart attack in your future | “The test is used by more people every year,” said Michael Blaha, co-director of the preventive cardiology program at Johns Hopkins University. Calcium scans quadrupled from 2006 to 2017, his research team reported, and Google searches for ... |
| 07.08.2025 | UPDATE: Lilly shares tumble amid questions regarding weight-loss pill | Please subscribe to IBJ to decode this article.
artep gdsooe rdm fy nesenorygiast g1tsa4tpeanh natda sadloeot.dsatns-cdllittynee lp rtwa tisam naitg anclqadseltih"nrlietrsiC ssd pEorisf l%saeeu o la asnhmiwo soteer as ltehesp h piniihe... |
| 07.08.2025 | Strand Therapeutics Raises $153M in Series B Financing | Strand Therapeutics, a Boston, MA-based company which specializes in new mRNA-based therapeutics, raised $153M in Series B funding.
The round was led by Kinnevik, with new investors Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Grou... |
| 04.08.2025 | Trump Demands Pharma Price Cuts: A New Era for U.S. Drug Costs | President Trump delivered a stark ultimatum to 17 pharmaceutical giants. He demands they slash U.S. drug prices to international "most favored nation" levels. Companies must commit by September 29. Failure risks severe government ... |
| 04.08.2025 | After Hengrui’s USD 500 million deal with GSK, which biotech firms are next in line? | Last month, Hengrui Pharmaceuticals announced a blockbuster licensing deal with GSK worth up to USD 12.5 billion, with an upfront payment of USD 500 million. The deal grants GSK the overseas rights to Hengrui’s HRS-9821 as well as exclusive... |
| 01.08.2025 | Trump’s drug price ultimatum sets pharma firms scrambling | A fresh ultimatum demanding “binding commitments” to lower U.S. drug prices sent pharma firms scrambling Friday.
President Trump sent letters to 17 major firms outlining the steps they must take to cut costs.
Healthcare stocks tumbled Frida... |
| 01.08.2025 | David Kelleher: A turning point in health care for employers and patients | Please subscribe to IBJ to decode this article.
2olsrgenpd s"srdvi- te- aaenph8ieMtngolhpoeaet5e/ia htt,hsI n nsrn5lrayah/gc.hrrlr"/c"lsl>hhxye e pa"a dd o
sb eioyom cni, hp ome. l hasrala n e tobrlc ovtavetah-tmph t ... |
| 31.07.2025 | Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days | President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
On Truth Social, Trump posted individual letters he sent 17 drugmakers, including Eli Lilly, GSK, Pfizer, Reg... |
| 29.07.2025 | Kyowa Kirin Announces Abstract Presentation at the European Academy of Dermatology and Venereology (EADV) Congress | PRINCETON, N.J. and TOKYO, July 29, 2025 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in pa... |
| 29.07.2025 | Trump’s pharmaceutical tariffs could affect some drugmakers more than others | President Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and they may have a bigger impact on some drugmakers than others.
AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-... |
| 21.07.2025 | FDA taps biotech industry veteran as RFK Jr.’s top drug regulator | The Food and Drug Administration said it has appointed former biotech executive George Tidmarsh as the agency’s top drug regulator.
Tidmarsh, an adjunct professor of pediatrics and neonatology at Stanford University’s School of Medicine, wi... |
| 08.07.2025 | Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo) | STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1],[2]
STOBOCLO and OSENVELT, among the first wave of biosimilars referencing PROLI... |
| 02.07.2025 | The Market's Dance: A Shift from Tech to Tradition | The stock market is a living organism. It breathes, pulses, and shifts with the rhythm of investor sentiment. Recently, it has taken a step back from the high-flying tech stocks that have dominated the landscape. Instead, it’s waltzing towa... |
| 02.07.2025 | 5 Things to Know
5 things to know before the stock market opens Wednesday | Stocks kicked off the second half of the year on a mixed note.
The Senate narrowly passed Trump’s spending package, sending it back to the House for approval.
Design software company Figma filed for an IPO.
Here are five key things investor... |
| 01.07.2025 | Levelpath's $55 Million Leap: Redefining Procurement with AI | In the bustling heart of San Francisco, a revolution is brewing. Levelpath, an AI-native procurement platform, has secured over $55 million in Series B funding. This infusion of capital propels the total raised to a staggering $100 million.... |
| 01.07.2025 | Stock futures inch higher after tech slide to start the second half: Live updates | Stock futures inched higher early Wednesday, after investors began the second half with a reduced appetite for technology stocks.
Futures tied to the Dow Jones Industrial Average added 69 points, or 0.2%. S&P 500 futures were up 0.1% al... |
| 30.06.2025 | Levelpath Raises $55+M in Series B Funding | Levelpath, a San Francisco, CA-based AI-native procurement platform provider, raised $55+m in Series B funding.
The round, which brought the total raised to $100m, was led by Battery Ventures, with participation from Redpoint Ventures, Benc... |
| 26.06.2025 | Microsoft tenta pôr Copilot em empresas, mas funcionários preferem ChatGPT | Microsoft tenta pôr Copilot nas empresas (ilustração: Vitor Pádua/Tecnoblog)
O melhor da tecnologia está no nosso canal no WhatsApp
Entre Agora Resumo
Empresas ampliaram o uso do ChatGPT após relatos positivos de funcionários, que preferem ... |
| 19.06.2025 | Big Pharma Under Fire: A Taxing Debate in the Senate | The Senate floor is heating up. Two Democratic lawmakers, Sen. Elizabeth Warren and Rep. Jan Schakowsky, are shining a spotlight on the pharmaceutical giants. Pfizer, Johnson & Johnson, Merck, AbbVie, and Amgen are in the crosshairs. Th... |
| 18.06.2025 | The Dawn of Radioligand Therapies: A New Era in Precision Oncology | In the realm of cancer treatment, innovation is the lifeblood that fuels hope. The latest beacon of this hope shines brightly on radioligand therapies (RLTs). These therapies are not just a whisper of potential; they are a clarion call for ... |
| 17.06.2025 | Stock futures slip ahead of the Federal Reserve’s rate decision: Live updates | U.S. stock futures inched lower on Tuesday night, as traders brace for the Federal Reserve’s rate policy decision due Wednesday afternoon.
Futures tied to the Dow Jones Industrial Average slipped 99 points, or 0.2%. S&P 500 futures shed... |
| 17.06.2025 | Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump’s plan | Two Democratic lawmakers on Tuesday pressed five of the nation’s largest pharmaceutical companies about their low tax bills and whether they support extending massive tax cuts for the industry in the GOP reconciliation bill.
Sen. Elizabeth ... |
| 13.06.2025 | Indianapolis-based startup leans on connections to treat brain diseases | Please subscribe to IBJ to decode this article.
so" co7tniifn:wct=l l5m=/nne4bBc_omtI"/ioaedel"-_oii=ii0-edidC5a2ru["00-mca5ae=fud othmtwi1ga"e"3r"daletl0ca]nsene d vy.sdstiheip =loto jee6teo mpts m3t [c6i... |
| 06.06.2025 | JPMorgan’s top biotech and pharma picks for the second half | - |
| 05.06.2025 | Beyond Surveys: How to Leverage Patient Communities for Real-World Evidence, Upcoming Webinar Hosted by Xtalks | www.inspireresearch.com
In this free webinar, learn how life sciences teams leverage engaged patient communities to generate richer, more meaningful RWE — beyond the limits of traditional surveys. Attendees will discover practical strategie... |
| 05.06.2025 | QureBio Ltd. Completes Nearly CNY 100 Million Series C1 Financing Led by Efung Capital, accelerating clinical progress in global competition for core pipelines | SHANGHAI, June 5, 2025 /PRNewswire/ -- Qure Biotechnology (Shanghai) Co., Ltd. (QureBio) announced that it has completed a Series C1 financing round. The financing raised nearly CNY 100 million (approximately USD 14 million) and was led exc... |
| 04.06.2025 | Health-care stocks are due for a turnaround after a historically bad month, according to the charts | - |
| 30.05.2025 | Navigating Change: EpiVax Welcomes New Leadership Amid Evolving Landscape of Immunogenicity | In the world of biotechnology, change is the only constant. EpiVax, a pioneer in immunogenicity assessment, has embraced this truth with the appointment of Dr. Vibha Jawa as Chief Scientific Officer. This strategic move signals a new chapte... |
| 28.05.2025 | These biotech stocks will benefit as generative AI speeds up drug discovery, Jefferies says | - |
| 28.05.2025 | EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO | PROVIDENCE, R.I., May 28, 2025 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity assessment for biologic therapeutics and vaccines, is pleased to announce the appointment of Vibha Jawa, PhD, FAAPS as Chief Scientific Offi... |
| 21.05.2025 | Lethal mutations in pregnancy loss | REYKJAVIK, Iceland, May 21, 2025 /PRNewswire/ -- In a study published in Nature today "Sequence diversity lost in early pregnancy," scientists from deCODE genetics, a subsidiary of Amgen, estimate that around one in 136 pregnancie... |
| 13.05.2025 | Trump’s Drug Price Plan: A Bold Move or a Pipe Dream? | In a bold stroke, President Donald Trump has revived a controversial policy aimed at slashing U.S. drug prices. The plan, known as the “most favored nation” policy, seeks to tie American drug prices to those in other developed countries, wh... |
| 12.05.2025 | Trump signs order aiming to cut some U.S. drug prices to match lower ones abroad | President Donald Trump revived a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.
Trump signed an executive order including several different actions... |
| 29.04.2025 | Перечень жизненно важных лекарств не резиновый | - |
| 28.04.2025 | Фармрынок идет на поправку | - |
| 25.04.2025 | Exclusive: US pharma tariffs would raise US drug costs by $51 billion annually, report finds | Exclusive: US pharma tariffs would raise US drug costs by $51 billion annually, report finds
By Maggie FickApril 25, 20254:34 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
U.S. dollar banknote... |
| 15.04.2025 | Назад, в генетическое будущее | - |
